Фармкомпания Viatris получила 40 млрд иен в кредит и подтвердила эффективность нового препарата

Компания Viatris Inc. заключила соглашение о получении 40 млрд иен в виде срочного необеспеченного кредита для финансирования деятельности и refinancing существующих обязательств. Ранее фармацевтический гигант сообщил о положительных результатах третьей фазы клинических испытаний препарата Nefecon при лечении иммуноглобулиновой болезни почек.

Перевод ИИ

Текст статьи доступен на языке оригинала.

Нажмите кнопку «Перевести статью» выше, чтобы сгенерировать перевод с помощью ИИ.

Оригинальный контент

Источник

Viatris Inc. (NASDAQ:VTRS) is one of the Top 10 Extreme Value Stocks To Buy Now. On July 1, Viatris Inc. (NASDAQ:VTRS) entered into a loan agreement with a group of lenders led by Mizuho Bank. The company secured a ¥40 billion senior unsecured term loan. This will support general business purposes and also refinance an existing loan of the same amount. The loan carries an interest rate based on the TIBO rate plus 1.10% and will mature in three years. The agreement is backed by guarantees from key subsidiaries of Viatris and includes financial conditions, such as limits on borrowing, dividend payments, and mergers. Moreover, the loan's pricing and conditions are tied to VTRS's credit ratings. This encourages the healthcare company to maintain healthy, investment-grade financial metrics. Earlier on June 29, Viatris Inc. (NASDAQ:VTRS) reported positive phase 3 results for Nefecon in primary immunoglobulin A nephropathy. The company said that it met primary and secondary endpoints in a Japanese trial. In the open-label study, patients taking Nefecon, also known as VR-205, showed a reduction in urine protein levels over time. After nine months, the urine protein-to-creatinine ratio fell by about 33.75% compared to baseline. The drug is approved in the US under the name Tarpeyo and marketed by Calliditas Therapeutics. Viatris Inc. (NASDAQ:VTRS) operates as a healthcare company. It operates in four segments. These include Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. While we acknowledge the potential of VTRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Iran Peace Deal Sends Oil Lower: Top 8 Travel Stocks to Buy Now and 8 Hidden Multibagger Stocks to Buy Now. Disclosure: None. Follow Insider Monkey on Google News.